- Home
- AFRI vs ETON Comparison
AFRI vs ETON Comparison
Compare AFRI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- ETON
- Stock Information
- Founded
- AFRI 1943
- ETON 2017
- Country
- AFRI Gibraltar
- ETON United States
- Employees
- AFRI N/A
- ETON N/A
- Industry
- AFRI Packaged Foods
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- ETON Health Care
- Exchange
- AFRI Nasdaq
- ETON Nasdaq
- Market Cap
- AFRI 275.5M
- ETON 329.8M
- IPO Year
- AFRI N/A
- ETON 2018
- Fundamental
- Price
- AFRI $10.14
- ETON $12.48
- Analyst Decision
- AFRI
- ETON Strong Buy
- Analyst Count
- AFRI 0
- ETON 2
- Target Price
- AFRI N/A
- ETON $15.00
- AVG Volume (30 Days)
- AFRI 10.7K
- ETON 176.9K
- Earning Date
- AFRI 01-14-2025
- ETON 11-12-2024
- Dividend Yield
- AFRI N/A
- ETON N/A
- EPS Growth
- AFRI N/A
- ETON N/A
- EPS
- AFRI N/A
- ETON N/A
- Revenue
- AFRI $305,476,000.00
- ETON $34,677,000.00
- Revenue This Year
- AFRI N/A
- ETON $22.25
- Revenue Next Year
- AFRI N/A
- ETON $80.27
- P/E Ratio
- AFRI N/A
- ETON N/A
- Revenue Growth
- AFRI 5.42
- ETON 5.64
- 52 Week Low
- AFRI $9.63
- ETON $3.03
- 52 Week High
- AFRI $12.00
- ETON $15.00
- Technical
- Relative Strength Index (RSI)
- AFRI 49.75
- ETON 51.87
- Support Level
- AFRI $10.01
- ETON $12.60
- Resistance Level
- AFRI $10.36
- ETON $15.00
- Average True Range (ATR)
- AFRI 0.27
- ETON 0.99
- MACD
- AFRI 0.01
- ETON -0.08
- Stochastic Oscillator
- AFRI 44.21
- ETON 24.06
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.